Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade

BMC Cancer

Volumn 10, Issue , 2010, Pages

  He, Mian ^a   Cheng, Yang ^b   Li, Wen ^a   Liu, Qiongshan ^a   Liu, Junxiu ^a   Huang, Jinghe ^c   Fu, Xiaodong ^c  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; CELL MEMBRANE PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MOESIN; PROTEIN ROCK 2; REGULATOR PROTEIN; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C; ACTIN BINDING PROTEIN; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; RHO KINASE; RHOA PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ARTICLE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL MOTION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; CANCER INVASION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; TIME; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ACTINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOSKELETON; ENZYME ACTIVATION; FEMALE; HUMANS; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 77951537257     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-170     Document Type: Article

References (48)

1. Sankaranarayanan R. Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S205-210. 10.1016/S0020-7292(06)60035-0, 17161159.
2. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006, 116(5):1167-1173. 10.1172/JCI28607, 1451224, 16670757.
3. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008, 5(4):206-219. 10.1038/ncponc1066, 2709494, 18253104.
4. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15(2):290-298. 449944, 8617204.
5. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009, 21(2):154-165. 10.1016/j.ceb.2008.12.012, 19230644.
6. Ueda M, Terai Y, Yamashita Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Hung YC, Ueki M. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 2002, 98(3):335-343. 10.1002/ijc.10193, 11920583.
7. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H, Kudo T. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 2001, 85(1):93-97. 10.1054/bjoc.2001.1846, 2363906, 11437408.
8. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K, Sekiya S. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005, 103(4):724-730. 10.1002/cncr.20819, 15637689.
9. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003, 201(4):544-554. 10.1002/path.1467, 14648657.
10. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006, 9(3):209-223. 10.1016/j.ccr.2006.02.018, 16530705.
11. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112(4):453-465. 10.1016/S0092-8674(03)00120-X, 12600310.
12. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol 2005, 17(5):559-564. 10.1016/j.ceb.2005.08.002, 16098726.
13. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001, 11(1):41-47. 10.1016/S0959-437X(00)00154-4, 11163149.
14. Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T. Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One 2008, 3(7):e2790. 10.1371/journal.pone.0002790, 2464736, 18665217.
15. Sanchez AM, Flamini MI, Fu XD, Mannella P, Giretti MS, Goglia L, Genazzani AR, Simoncini T. Rapid Signaling of Estrogen to Wave1 and Moesin Controls Neuronal Spine Formation Via the Actin Cytoskeleton. Mol Endocrinol 2009, 23(8):1193-202. 10.1210/me.2008-0408, 19460862.
16. Fu XD, Flamini M, Sanchez AM, Goglia L, Giretti MS, Genazzani AR, Simoncini T. Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod 2008, 14(4):225-234. 10.1093/molehr/gan010, 18308736.
17. Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfor K, Kristensen GB, Stokke T. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006, 7:268. 10.1186/1471-2164-7-268, 1626467, 17054779.
18. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, et al. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One 2008, 3(5):e2238. 10.1371/journal.pone.0002238, 2375059, 18493596.
19. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res 2004, 10(18 Pt 1):6239-6247. 10.1158/1078-0432.CCR-04-0242, 15448013.
20. Shin HY, Smith ML, Toy KJ, Williams PM, Bizios R, Gerritsen ME. VEGF-C mediates cyclic pressure-induced endothelial cell proliferation. Physiol Genomics 2002, 11(3):245-251.
21. Simoncini T, Scorticati C, Mannella P, Fadiel A, Giretti MS, Fu XD, Baldacci C, Garibaldi S, Caruso A, Fornari L, et al. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 2006, 20(8):1756-1771. 10.1210/me.2005-0259, 16601072.
22. Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001, 7(11):3491-3494.
23. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003, 98(6):1217-1222. 10.1002/cncr.11529, 12973845.
24. Liu XE, Sun XD, Wu JM. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004, 10(3):352-355.
25. Tang RF, Itakura J, Aikawa T, Matsuda K, Fujii H, Korc M, Matsumoto Y. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas 2001, 22(3):285-292. 10.1097/00006676-200104000-00010, 11291931.
26. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 2008, 110(3):445-451. 10.1016/j.ygyno.2008.04.038, 18565574.
27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676. 10.1038/nm0603-669, 12778165.
28. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007, 96(4):541-545. 10.1038/sj.bjc.6603487, 2360045, 17164762.
29. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18(1):4-25. 10.1210/er.18.1.4, 9034784.
30. Marchio S, Primo L, Pagano M, Palestro G, Albini A, Veikkola T, Cascone I, Alitalo K, Bussolino F. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 1999, 274(39):27617-27622. 10.1074/jbc.274.39.27617, 10488101.
31. Zhao R, Liu XQ, Wu XP, Liu YF, Zhang ZY, Yang GY, Guo S, Niu J, Wang JY, Xu KS. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett 2010, 287(2):150-6. 10.1016/j.canlet.2009.06.006, 19581046.
32. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003, 28(9):488-494. 10.1016/S0968-0004(03)00193-2, 13678960.
33. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005, 96(7):379-386. 10.1111/j.1349-7006.2005.00062.x, 16053508.
34. Flamini MI, Fu XD, Sanchez AM, Giretti MS, Garibaldi S, Goglia L, Pisaneschi S, Tosi V, Genazzani AR, Simoncini T. Effects of Raloxifene on Breast Cancer Cell Migration and Invasion through the Actin Cytoskeleton. J Cell Mol Med 2009, 13(8B):2396-407. 10.1111/j.1582-4934.2008.00505.x, 18798864.
35. Fu XD, Giretti MS, Goglia L, Flamini MI, Sanchez AM, Baldacci C, Garibaldi S, Sitruk-Ware R, Genazzani AR, Simoncini T. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer 2008, 8:166. 10.1186/1471-2407-8-166, 2443160, 18541028.
36. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998, 95(24):14389-14394. 10.1073/pnas.95.24.14389, 24383, 9826710.
37. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Huot J. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000, 275(14):10661-10672. 10.1074/jbc.275.14.10661, 10744763.
38. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell 2000, 92(5):305-316. 10.1016/S0248-4900(00)01078-9, 11071040.
39. Tsukita S, Yonemura S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem 1999, 274(49):34507-34510. 10.1074/jbc.274.49.34507, 10574907.
40. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007, 24(2):69-78. 10.1007/s10585-006-9050-x, 17370041.
41. Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, Taniguchi S. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res 2004, 10(2):572-580. 10.1158/1078-0432.CCR-1323-03, 14760079.
42. Menager C, Vassy J, Doliger C, Legrand Y, Karniguian A. Subcellular localization of RhoA and ezrin at membrane ruffles of human endothelial cells: differential role of collagen and fibronectin. Exp Cell Res 1999, 249(2):221-230. 10.1006/excr.1999.4481, 10366421.
43. Vaiskunaite R, Adarichev V, Furthmayr H, Kozasa T, Gudkov A, Voyno-Yasenetskaya TA. Conformational activation of radixin by G13 protein alpha subunit. J Biol Chem 2000, 275(34):26206-26212. 10.1074/jbc.M001863200, 10816569.
44. Sun H, Breslin JW, Zhu J, Yuan SY, Wu MH. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation 2006, 13(3):237-247. 10.1080/10739680600556944, 16627366.
45. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 2003, 23(2):211-217. 10.1161/01.ATV.0000054198.68894.88, 12588761.
46. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009, 28(1-2):65-76. 10.1007/s10555-008-9170-7, 19160018.
47. Faried A, Faried LS, Usman N, Kato H, Kuwano H. Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol 2007, 14(12):3593-3601. 10.1245/s10434-007-9562-x, 17896152.
48. Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ, Schultz PG, Huang Q. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci USA 2007, 104(16):6696-6701. 10.1073/pnas.0701145104, 1871848, 17420453.